Granted Patent
B2
US 12,201,638 · App. 18/621,023 · Granted Jan 21, 2025
Pharmaceutical compositions comprising (2S)-n-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
Inventors:
Håkan Wikström (Mölndal, SE); Jufang Wu Ludvigsson (Mölndal, SE); Thomas Andersson (Mölndal, SE)
Assignee:
ASTRAZENECA AB
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof.
Claims (15)
1. A pharmaceutical composition comprising:
(a) from about 3 wt % to about 15 wt % of (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl) phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A);
(b) from about 55 wt % to about 70 wt % microcrystalline cellulose;
(c) from about 18 wt % to about 22 wt % dibasic calcium phosphate dihydrate;
(d) from about 3.5 wt % to about 4.5 wt % sodium starch glycolate;
(e) from about 0.05 wt % to about 0.50 wt % silicon dioxide; and
(f) from about 2.5 wt % to about 7 wt % glycerol behenate;
and wherein the weights of components (a)-(f) add up to 100 wt %.
2. The pharmaceutical composition of claim 1 , wherein the composition is in tablet form.
3. The pharmaceutical composition of claim 2 , wherein the composition further comprises a tablet coat.
4. The pharmaceutical composition of claim 1 , wherein Compound A is present at from about 5 mg to about 50 mg in the composition.
5. The pharmaceutical composition of claim 1 , wherein Compound A is present at from about 10 mg to about 40 mg in the composition.
6. The pharmaceutical composition of claim 1 , wherein Compound A is present at 10 mg in the composition.
7. The pharmaceutical composition of claim 1 , wherein Compound A is present at 25 mg in the composition.
8. The pharmaceutical composition of claim 1 , wherein Compound A is present at 40 mg in the composition.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 3, 2024
From: WIKSTRÖM, HÅKAN; LUDVIGSSON, JUFANG WU; ANDERSSON, THOMAS
To: ASTRAZENECA AB
Reel/Frame 066998/0673 →
Continuity (3)
Continuation
16975292
Provisional Application
62636944
· Mar 1, 2018
References Cited (364)
US 8552034B2
· Verwijs et al.
· 2013
[cited by applicant]
US 8871783B2
· Anderskewitz et al.
· 2014
[cited by applicant]
US 8877775B2
· Anderskewitz et al.
· 2014
[cited by applicant]
US 8889708B2
· Grauert et al.
· 2014
[cited by applicant]
US 8987249B2
· Anderskewitz et al.
· 2015
[cited by applicant]
US 8999975B2
· Grundl et al.
· 2015
[cited by applicant]
US 9073869B2
· Anderskewitz et al.
· 2015
[cited by applicant]
US 9440960B2
· Grauert et al.
· 2016
[cited by applicant]
US 9522894B2
· Lonn et al.
· 2016
[cited by applicant]
US 9713606B2
· Anderskewitz et al.
· 2017
[cited by applicant]
US 9815805B2
· Lonn et al.
· 2017
[cited by applicant]
US 9856228B2
· Lauritzen et al.
· 2018
[cited by applicant]
US 9879026B2
· Vintonyak et al.
· 2018
[cited by applicant]
US RE47636E
· Vintonyak et al.
· 2019
[cited by applicant]
US 20080221093A1
· Gege et al.
· 2008
[cited by applicant]
US 20110236367A1
· Olsen et al.
· 2011
[cited by applicant]
US 20120329775A1
· Ford et al.
· 2012
[cited by applicant]
US 20150105375A1
· Anderskewitz et al.
· 2015
[cited by applicant]
US 20160061824A1
· Hahn et al.
· 2016
[cited by applicant]
US 20170027907A1
· Legangneux et al.
· 2017
[cited by applicant]
US 20180028541A1
· Lonn et al.
· 2018
[cited by applicant]
US 20180169017A1
· Desai et al.
· 2018
[cited by applicant]
US 20190091236A1
· Lonn et al.
· 2019
[cited by applicant]
US 20190167636A1
· Anderskewitz et al.
· 2019
[cited by applicant]
US 20190247400A1
· Dipetrillo et al.
· 2019
[cited by applicant]
US 20200138780A1
· Anderskewitz et al.
· 2020
[cited by applicant]
US 20200179398A1
· Lonn et al.
· 2020
[cited by applicant]
US 20200390781A1
· Dipetrillo et al.
· 2020
[cited by applicant]
US 20210186984A1
· Dipetrillo et al.
· 2021
[cited by applicant]
US 20210252015A1
· Zhang
· 2021
[cited by applicant]
US 20220133737A1
· Lonn et al.
· 2022
[cited by applicant]
US 20230250071A1
· Lönn et al.
· 2023
[cited by applicant]
US 20240041896A1
· Lonn et al.
· 2024
[cited by applicant]
US 20240226112A1
· Usansky et al.
· 2024
[cited by applicant]
CN 101945851A
· 2011
[cited by applicant]
CN 102574830A
· 2012
[cited by applicant]
CN 112920124A
· 2021
[cited by applicant]
EP 1317555B1
· 2007
[cited by applicant]
EP 2840083A1
· 2015
[cited by applicant]
JP 2006527704A
· 2006
[cited by applicant]
JP 2008501692A
· 2008
[cited by applicant]
JP 2008504307A
· 2008
[cited by applicant]
JP 2010540526A
· 2010
[cited by applicant]
JP 2011506421A
· 2011
[cited by applicant]
JP 2011522011A
· 2011
[cited by applicant]
JP 2012522764A
· 2012
[cited by applicant]
JP 2012526093A
· 2012
[cited by applicant]
JP 2016515576A
· 2016
[cited by applicant]
JP 2017503832A
· 2017
[cited by applicant]
JP 2019070029A
· 2019
[cited by applicant]
JP 2021046423A
· 2021
[cited by applicant]
TW 201041889A
· 2010
[cited by applicant]
WO WO9917777A1
· 1999
[cited by applicant]
WO WO0116108A2
· 2001
[cited by applicant]
WO WO0196285A1
· 2001
[cited by applicant]
WO WO02051831A1
· 2002
[cited by applicant]
WO WO03048123A1
· 2003
[cited by applicant]
WO WO2004076434A1
· 2004
[cited by applicant]
WO WO2004087153A2
· 2004
[cited by applicant]
WO WO2004106289A1
· 2004
[cited by applicant]
WO WO2004110988A1
· 2004
[cited by applicant]
WO WO2005106012A2
· 2005
[cited by applicant]
WO WO2005107762A2
· 2005
[cited by applicant]
WO WO2005120465A2
· 2005
[cited by applicant]
WO WO2006000228A2
· 2006
[cited by applicant]
WO WO2006020145A2
· 2006
[cited by applicant]
WO WO2007005668A2
· 2007
[cited by applicant]
WO WO2008109180A2
· 2008
[cited by applicant]
WO WO2008109181A2
· 2008
[cited by applicant]
WO WO2009026701A1
· 2009
[cited by applicant]
WO WO2009042187A1
· 2009
[cited by applicant]
WO WO2009074829A1
· 2009
[cited by applicant]
WO WO2009147238A1
· 2009
[cited by applicant]
WO WO2010077680A2
· 2010
[cited by applicant]
WO WO2010114405A2
· 2010
[cited by applicant]
WO WO2010128324A1
· 2010
[cited by applicant]
WO WO2010142985A1
· 2010
[cited by applicant]
WO WO2011154677A1
· 2011
[cited by applicant]
WO WO2012064715A1
· 2012
[cited by applicant]
WO WO2012119941A1
· 2012
[cited by applicant]
WO WO2013041497A1
· 2013
[cited by applicant]
WO WO2014091443A1
· 2014
[cited by applicant]
WO WO2014140075A1
· 2014
[cited by applicant]
WO WO2014140081A1
· 2014
[cited by applicant]
WO WO2014140091A1
· 2014
[cited by applicant]
WO WO2014151784A1
· 2014
[cited by applicant]
WO WO2014165303A1
· 2014
[cited by applicant]
WO WO2015032942A1
· 2015
[cited by applicant]
WO WO2015032943A1
· 2015
[cited by applicant]
WO WO2015032945A1
· 2015
[cited by applicant]
WO WO2015110826A1
· 2015
[cited by applicant]
WO WO2015175939A1
· 2015
[cited by applicant]
WO WO2016075240A1
· 2016
[cited by applicant]
WO WO2018022978A1
· 2018
[cited by applicant]
WO WO2019157050A1
· 2019
[cited by applicant]
WO WO2019166626A1
· 2019
[cited by applicant]
WO WO2020018547A1
· 2020
[cited by applicant]
WO WO2020018551A1
· 2020
[cited by applicant]
WO WO2020247665A1
· 2020
[cited by applicant]
WO WO2022140516A1
· 2022
[cited by applicant]
WO WO2022232420A1
· 2022
[cited by applicant]
WO WO2022232573A1
· 2022
[cited by applicant]
WO WO2023076615A1
· 2023
[cited by applicant]
WO WO2023159120A1
· 2023
[cited by applicant]
Ludvigsson et al. Journal of Pharmaceutical and Biomedical Analysis 158 (2018) 82-87, “Degradation caused by incompatibility between sodium stearyl fumarate (PRUV) and AZD7986 in the drug product” (Year: 2018).
[cited by examiner]
Wang et al. European Journal of Pharmaceutics and Biopharmaceutics 75 (2010), 1-15, “Lubrication in tablet formulations” (Year: 2010).
[cited by examiner]
Li et al. Lubricants 2014, 2, 21-43; doi: 10.3390/lubricants2010021, “Lubricants in Pharmaceutical Solid Dosage Forms” (Year: 2014 ).
[cited by examiner]
Adkison, A. M. et al. (2002), “Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis,” J. Clin. Invest. 109(3):363-371.
[cited by applicant]
Alpsoy, E. (Apr. 2005), “Behcet's Disease: Treatment of Mucocutaneous Lesions,” Clinical and Experimental Rheumatology, vol. 23, No. 4, pp. 532-539.
[cited by applicant]
Avci, D. (Feb. 2019), “Dipeptidyl Peptidase-4 Inhibitors and Inflammation: Dpp-4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level,” Journal of Biosciences and Medicines, vol. 7, No. 2, pp. 4…
[cited by applicant]
Bae, S. et al. (Jul. 2012), “Elevated interleukin-32 expression in granulomatosis with polyangiitis,” Rheumatology 2012;51:1979-1988, doi:10.1093/rheumatology/kes163, Advance Access publication.
[cited by applicant]
Birmingham Vasculitis Activity Score (version 3), 1 page [No Date].
[cited by applicant]
Birring, S. S. et al. (2003), “Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ),” Thorax; 58:339-343.
[cited by applicant]
Bondebjerg, J. et al. (2005), “Novel semicarbazide-derived inhibitors of human dipeptidyl peptidase I (hDPPI),” Bioorg Med Chem; 13:4408-4424.
[cited by applicant]
Bondejberg, J. et al. (2006), “Dipeptidyl Nitriles as Human Dipeptidyl Peptidase 1 Inhibitors,” Bioorg Med Chem Lett; 16:3614-3617.
[cited by applicant]
Bragg, R. A. et al. (Sep. 2015), “Aortic Binding of AZD5248: Mechanistic Insight and Reactivity Assays To Support Lead Optimization,” Chem Res Toxicol. Oct. 19, 2015;28(10):1991-1999.
[cited by applicant]
Cartin-Ceba, R. et al. (Nov. 2012), “Rituximab for Remission Induction and Maintenance in Refractory Granulomatosis With Polyangiitis (Wegener's),” Arthritis & Rheumatism, vol. 64, No. 11, pp. 3770-3778.
[cited by applicant]
Chalmers, J. D. et al. (2017), “Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis,” Am J Respir Crit Care Med, 195(10):1384-1393.
[cited by applicant]
Chalmers, J. D. et al. (Mar. 2014), “The Bronchiectasis Severity Index. An International Derivation and Validation Study,” Am. J. Respir. Crit. Care Med., 189(5):576-585.
[cited by applicant]
Chalmers, J. D. et al. (Nov. 2020), “Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis,” N Engl J Med ;383(22):2127-2137.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Aug. 15, 2017, 5 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Aug. 20, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Dec. 11, 2020, 10 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Dec. 17, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Dec. 17, 2019, 10 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Dec. 4, 2019, 10 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Dec. 8, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Feb. 11, 2019, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Feb. 12, 2019, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Feb. 5, 2018, 5 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Jan. 14, 2019, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Jan. 28, 2019, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Jan. 3, 2019, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Jan. 31, 2019, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Jul. 12, 2017, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Jul. 30, 2018, 5 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Mar. 28, 2019, 16 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on May 28, 2019, 10 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Nov. 13, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Nov. 28, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Nov. 6, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Oct. 16, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Sep. 12, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT03218917, ClinicalTrials.gov submitted on Sep. 24, 2018, 17 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Apr. 12, 2022, 33 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Apr. 22, 2021, 14 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Apr. 22, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Apr. 5, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Apr. 9, 2021, 13 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Aug. 1, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Aug. 18, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Aug. 23, 2021, 24 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Aug. 30, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Aug. 9, 2021, 23 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Dec. 1, 2020, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Dec. 10, 2020, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Dec. 3, 2021, 28 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jul. 11, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jul. 23, 2021, 21 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jul. 27, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jul. 9, 2021, 21 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jun. 20, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jun. 21, 2021, 19 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jun. 24, 2021, 19 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jun. 30, 2021, 20 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jun. 7, 2021, 19 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Jun. 7, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Mar. 11, 2021, 9 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Mar. 25, 2021, 11 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Mar. 25, 2022, 34 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Mar. 4, 2022, 32 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on May 13, 2022, 33 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on May 25, 2022, 31 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Nov. 10, 2021, 29 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Nov. 15, 2022, 30 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Nov. 19, 2020, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Nov. 23, 2022, 30 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Oct. 10, 2022, 31 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Oct. 14, 2020, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Oct. 27, 2022, 31 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Oct. 28, 2021, 29 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Oct. 29, 2021, 29 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Oct. 8, 2021, 28 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Sep. 12, 2022, 31 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Sep. 27, 2022, 31 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04594369. ClinicalTrials.gov submitted on Sep. 7, 2021, 25 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04817332. ClinicalTrials.gov submitted on Aug. 12, 2021, 8 pages.
[cited by applicant]
Clinical Trials Identifier: NCT04817332. ClinicalTrials.gov submitted on Mar. 25, 2021, 8 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Apr. 14, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Apr. 5, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Aug. 23, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Dec. 3, 2021, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Jul. 27, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Jul. 29, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Jul. 4, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Jun. 22, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Jun. 7, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Mar. 8, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on May 13, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on May 25, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Nov. 10, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Oct. 12, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Oct. 14, 2021, 5 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Oct. 29, 2021, 5 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05090904. ClinicalTrials.gov submitted on Sep. 9, 2022, 7 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05344508. ClinicalTrials.gov submitted on Apr. 18, 2022, 3 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05344508. ClinicalTrials.gov submitted on Aug. 3, 2022, 3 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05344508. ClinicalTrials.gov submitted on Oct. 6, 2022, 3 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05355935. ClinicalTrials.gov submitted on Apr. 26, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05355935. ClinicalTrials.gov submitted on Aug. 16, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05355935. ClinicalTrials.gov submitted on Jul. 27, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05355935. ClinicalTrials.gov submitted on Jul. 5, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05355935. ClinicalTrials.gov submitted on Jun. 7, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05355935. ClinicalTrials.gov submitted on May 16, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05355935. ClinicalTrials.gov submitted on Oct. 19, 2022, 5 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05355935. ClinicalTrials.gov submitted on Sep. 9, 2022, 6 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05517525. ClinicalTrials.gov submitted on Aug. 24, 2022, 5 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05517525. ClinicalTrials.gov submitted on Nov. 7, 2022, 4 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05517525. ClinicalTrials.gov submitted on Oct. 17, 2022, 4 pages.
[cited by applicant]
Clinical Trials Identifier: NCT05517525. ClinicalTrials.gov submitted on Sep. 21, 2022, 5 pages.
[cited by applicant]
Dadoniene, J. et al. (2017), “Clinical characteristics and long-term survival differences of the ANCA-associated vasculitis group: a cross-sectional study of 27 patients,” ACTA Medica Lituanica, vol. 24, No. 2, pp. 107-…
[cited by applicant]
Doyle, K. et al. (Oct. 2016), “Discovery of second generation reversible covalent DPP1 inhibitors leading to an Oxazepane Amidoacetonitrile based clinical candidate (AZD7986),” Journal of Medicinal Chemistry, 59(20):945…
[cited by applicant]
Everts-Graber, J. et al. (2019), “Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance,” Kid…
[cited by applicant]
Extended European Search Report for European Application No. 17195612.1, mailed Mar. 21, 2018, 5 pages.
[cited by applicant]
Extended European Search Report for European Application No. 17835331.4, mailed Feb. 11, 2020, 8 pages.
[cited by applicant]
Extended European Search Report for European Application No. 19751012.6, dated Oct. 4, 2021, 7 pages.
[cited by applicant]
Extended European Search Report for European Application No. 19837016.5, mailed Mar. 18, 2022, 10 pages.
[cited by applicant]
Extended European Search Report for European Application No. 19838400.0, mailed Mar. 24, 2022, 9 pages.
[cited by applicant]
Extended European Search Report for European Application No. 20173862.2, mailed Sep. 11, 2020, 7 pages.
[cited by applicant]
Falk, R. J. et al. (Jun. 1990) “Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro,” Proc. Natl. Acad. Sci. USA, vol. 87, pp. 4115-4119.
[cited by applicant]
Floris, A. et al. (Apr. 2016), “Using the Birmingham vasculitis activity score as a screening tool in patients with suspected vasculitis,” i174, Poster Viewing III, Retrieved from the Internet: URL: https://academic.oup…
[cited by applicant]
Furber, M. et al. (2014), “Cathepsin C Inhibitors: Property Optimization and Identification of a Clinical Candidate,” Journal of Medicinal Chemistry, vol. 57, pp. 2357-2367.
[cited by applicant]
Gardiner, P. et al. (2016), “Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity,” Br J Pharmacol; 173:2390-401.
[cited by applicant]
Geetha, D. et al. (2015), “Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab,” J Nephrol 28:17-27.
[cited by applicant]
Goeminne, P. C. et al. (Feb. 2014), “Mortality in non-cystic fibrosis bronchiectasis: A prospective cohort analysis,” Respir. Med., 108(2):287-296.
[cited by applicant]
Golchert, D. et al. (Sep. 2013), “Evaluation of some compression aids in tableting of roller compacted swellable core drug layer,” Int J Pharm., 453(2):322-328.
[cited by applicant]
Guarino, C. et al. (2017), “Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases,” Biochem Pharmacol; 131:52-67.
[cited by applicant]
Guay, D. et al. (2009), “Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C,” Bioorg Med Chem Lett; 19:5392-5396.
[cited by applicant]
Guay, D. et al. (2010), “Therapeutic Utility and Medicinal chemistry of Cathepsin C Inhibitors,” Curr Top Med Chem; 10:708-716.
[cited by applicant]
Guillevin, L. et al. (Mar. 1999), “Microscopic Polyangiitis,” Arthritis & Rheumatism, vol. 42, No. 3, pp. 421-430.
[cited by applicant]
Insmed, (Feb. 2020), “Insmed Announces Positive Top-Line Results from Phase 2 WILLOW Study ofINS1007 in Patients with Non-Cystic Fibrosis Bronchiectasis,” 5 pages.
[cited by applicant]
Insmed, “Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor,” Oct. 2016, 3 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2019/055138, mailed Jul. 19, 2019, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/GB2015/050155, mailed Mar. 6, 2015, 7 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/044343, mailed Oct. 12, 2017, 7 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/016844, mailed May 31, 2019, 10 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/042021, mailed Sep. 4, 2019, 7 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/042026, mailed Sep. 4, 2019, 7 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/064810, mailed Mar. 16, 2022, 8 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/026769, mailed Sep. 9, 2022, 15 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/027026, mailed Sep. 14, 2022, 11 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/062731, dated May 30, 2023, 32 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2022/026769, mailed Jun. 27, 2022, 3 pages.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2022/027026, mailed Jul. 8, 2022, 2 pages.
[cited by applicant]
Jarrot, P-A et al. (Jul. 2016), “Review Pathogenesis of ANCA-associated vasculitis: An update,” Autoimmunity Reviews, vol. 15, Issue 7, pp. 704-713.
[cited by applicant]
Jenne, D. E. (Aug. 1990), “Wegener's autoantigen decoded,” Nature, vol. 346, p. 520.
[cited by applicant]
Jennette, J. C. (2011), “Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener's granulomatosis),” Clinical and Experimental Immunology, 164 (Suppl. 1), pp. 7-10.
[cited by applicant]
Jones, B. E. et al. ( 2017), “Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis,” J Am Soc Nephrol 28: 1175-1187. doi: 10.1681/ASN.2016050548.
[cited by applicant]
Kallenberg, C. G. M. et al. (Dec. 2006), “Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides,” Nature Clinical Practice Rheumatology, vol. 2, No. 12, pp. 661-670.
[cited by applicant]
Karthik, V. V. (Jun. 2016), “Excipients Used in the Formulation of Tablets,” RRJCHEM, 5(2):143-154.
[cited by applicant]
Kelly, M. G. et al. (Sep. 2003), “Bronchiectasis in secondary care: A comprehensive profile of a neglected disease,” Eur. J. Intern. Med., 14(8):488-492.
[cited by applicant]
Keogh, K. A. et al. (2006), “Rituximab for Refractory Wegener's Granulomatosis. Report of a Prospective, Open-Label Pilot Trial,” Am J Respir Crit Care Med vol. 173. pp 180-187.
[cited by applicant]
Kettritz, R. ( Jun. 2008), “Autoimmunity in kidney diseases,” The Scandinavian Journal of Clinical & Laboratory Investigation, vol. 68, No. S241, 99-103.
[cited by applicant]
Knopf, A. et al. (2015), “Clinical aspects of granulomatosis with polyangiitis affecting the head and neck,” Eur Arch Otorhinolaryngol 272:185-193.
[cited by applicant]
Kono, H., et al. (Oct. 2012), “The IL-1-dependent sterile inflammatory response has a substantial caspase-1-independent component that requires cathepsin C,” The Journal of Immunology, vol. 189, No. 7, pp. 3734-3740.
[cited by applicant]
Korkmaz, B. et al. (2013), “Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C)as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis),” Semin Immunopathol, 35:411-421.
[cited by applicant]
Korkmaz, B. et al. (2018) “Therapeutic targeting of cathepsin C: from pathophysiology to treatment,” Pharmacol Ther; 190:202-236.
[cited by applicant]
Korkmaz, B. et al. (2019), “Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C,” Biochem Pharmacol ;164:349-367.
[cited by applicant]
Korkmaz, B. et al. (2020), “Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?” J Med Chem ;63:13258-13265. doi:10.1021/acs.jmedchem.0c00776.
[cited by applicant]
Korkmaz, B. et al., “Cathepsin C inhibition as a potential treatment strategy in cancer,” Biochemical Pharmacology, 194 (Dec. 2021):114803, 15 pages.
[cited by applicant]
Korkmaz, B. et al. (Nov. 2010), “Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases,” Pharmacological Reviews, vol. 62, No. 4, pp. 726-759.
[cited by applicant]
Laine, D. I. et al. (2010), “Discovery of novel cyanamide-based inhibitors of cathepsin C,” ACS Med Chem Lett.;2(2):142-147.
[cited by applicant]
Laine, D. I. et al. (2010), “Inhibitors of Cathepsin C (DPPI),” Expert Rev. Ther Pat; 20: 497-506.
[cited by applicant]
Li, J. et al. (2014), “Lubricants in Pharmaceutical Solid Dosage Forms,” Lubricants, 2:21-43.
[cited by applicant]
Lins, L. et al. (2016), “SF-36 total score as a single measure of health-related quality of life: Scoping review,” SAGE Open Medicine, vol. 4:1-12.
[cited by applicant]
Ludvigsson, J. W. et al. (2018), “Degradation caused by incompatibility between sodium stearyl fumarate (PRUV) and AZD7986 in the drug product,” Journal of Pharmaceutical and Biomedical Analysis, 158:82-87.
[cited by applicant]
Luqmani, R. A. et al. (1994), “Birmingham Vasculitis Activity Score (BVAS) in Systemic Necrotizing Vasculitis,” Q. J. Med; 87:671-678.
[cited by applicant]
Mcshane, P. J. et al. (2013), “Non-cystic fibrosis bronchiectasis,” Am J Respir Crit Care Med; 188(6):647-656. doi: 10.1164/rccm.201303-0411CI.
[cited by applicant]
Methot, N. et al. (2008), “In Vivo Inhibition of Serine Protease Processing Requires a High Fractional Inhibition of Cathepsin C,” Mol. Pharm; 73(6):1857-1865.
[cited by applicant]
Methot, N. et al. (Jul. 2007), “Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent proenzyme processing,” J. Biol. Chem., 282(29):20836-20846.
[cited by applicant]
Miller, B. E. et al. (2017), “Epithelial desquamation observed in a Phase I study of an oral cathepsin C inhibitor (GSK2793660),” Br J Clin Pharmacol;83(12):2813-2820. doi:10.1111/bcp.13398.
[cited by applicant]
Miller, M. R. et al. (2005), “Standardisation of spirometry,” Eur. Respir. J; 26:319-338.
[cited by applicant]
Mukhtyar, C. et al. (2009), “Modification and validation of the Birmingham Vasculitis Activity Score (version 3),” Ann Rheum Dis;68:1827-1832.
[cited by applicant]
Murray, M. P. et al. (2009), “Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis,” Eur Respir J; 34: 361-364.
[cited by applicant]
Murray, M. P. et al. (2009), “Validation of the Leicester Cough Questionnaire in non- cystic fibrosis bronchiectasis,” Eur Respir J; 34: 125-131.
[cited by applicant]
Pagnoux, C. et al. (2015), “Treatment of granulomatosis with polyangiitis (Wegener's),” Expert Review of Clinical Immunology, 11:3, 339-348.
[cited by applicant]
Pagnoux, C. et al. (2016), “Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome),” Expert Review of Clinical Immunology, vol. 12, No. 10, pp. 1059-106…
[cited by applicant]
Palmer, R. et al. (2018), “Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects,” Clin Pharmacol Ther; 104(6):1155-1164. doi:10.1…
[cited by applicant]
Pham, C. T. (Jul. 2006), “Neutrophil serine proteases: specific regulators of inflammation,” Nat. Rev. Immunol; 6:541-550.
[cited by applicant]
Popa, E. R. et al. (1999), “Differential B- and T-cell activation in Wegener's granulomatosis,” J Allergy Clin Immunol ;103:885-894.
[cited by applicant]
Pubchem, CID 134527801, “(2S)-2-[[Hydroxy-[(2S)-1,4-oxazepan-2-yl]methyl]amino]-3-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]propanenitrile,” Jun. 23, 2018, Retrieved from the Internet: URL: https://pubchem.ncbi.nlm.…
[cited by applicant]
Rawn, S. et al. (2014), “Purpura, petechiae, and bullae as first signs of juvenile granulomatosis with polyangiitis,” Eur J Pediatr 173:1685-1689.
[cited by applicant]
Rehm, S. R. T. et al. (2019), “Premedication with a cathepsin C inhibitor alleviates early primary graft dysfunction in mouse recipients after lung transplantation,” Sci Rep;9(1):9925-9933.
[cited by applicant]
Schirmer, J. H. et al. (2016), “Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort,” Rheumatology, 55:71-79.
[cited by applicant]
Schreiber, A. et al. (Mar. 2012), “Neutrophil serine proteases promote IL-1β generation and injury in necrotizing crescentic glomerulonephritis,” Journal of the American Society of Nephrology, vol. 23, No. 3, pp. 470-48…
[cited by applicant]
Selga, D. et al. (2006), “Polyarteritis nodosa when applying the Chapel Hill nomenclature—a descriptive study on ten patients,” Rheumatology;45:1276-1281.
[cited by applicant]
Shapiro, S. C. et al. (2016), “Inflammatory bowel disease mimicking granulomatosis with polyangiitis: a case report,” Journal of Medical Case Reports 10:214, 5 pages.
[cited by applicant]
Stenton, “The MRC breathlessness scale” Occupational Med., May 2008, 58:226-227.
[cited by applicant]
Stockley, R. et al., (Feb. 2013), “Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis,” Respiratory Medicine, vol. 107, No. 4, pp. 524-533.
[cited by applicant]
Stone, J. H. et al., (Apr. 2001), “A Disease-Specific Activity Index for Wegener's Granulomatosis,” Arthritis & Rheumatism, vol. 44, No. 4, pp. 912-920.
[cited by applicant]
Suka, M. et al. (2012), “Improvement in health-related quality of life in MPO-ANCA-associated vasculitis patients treated with cyclophosphamide plus prednisolone: an analysis of 18 months of follow-up data from the JMAA…
[cited by applicant]
Suppiah, R. et al., (2011), “A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis,” Rheumatology;50:899-905.
[cited by applicant]
Trouvin, A.-P. et al. (2014), “Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study,” Clinical and Exper…
[cited by applicant]
U.S. National Library of Medicine, “Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Efficacy, Safety & Tolerability, and Pharmacokinetics of INS1007 Administered Daily for 24 Weeks in…
[cited by applicant]
Von Vietinghoff, S. et al., (2005), “Membrane proteinase 3 and Wegener's granulomatosis,” Clinical Nephrology, vol. 64, No. 4, pp. 453-459.
[cited by applicant]
Wang, J. et al. (2010), “Lubrication in tablet formulations,” European Journal of Pharmaceutics and Biopharmaceutics, 75:1-15.
[cited by applicant]
Wickremasinghe, M. et al. (2005), “Non-tuberculous mycobacteria in patients with bronchiectasis,” Thorax, 60(12):1045-1051.
[cited by applicant]
Yates, M. et al. (2016), “EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis,” Ann Rheum Dis 75:1583-1594.
[cited by applicant]
Zhang, J. et al. (2019), “INS1007, a Reversible Dipeptidyl Peptidase 1 Inhibitor, Ameliorates Interferon-alpha-Accelerated Lupus Nephritis in Mice,” Abstract Review, 17th International Congress of Immunology. Abstract: …
[cited by applicant]
Zhang, J. et al. (2019), “The Reversible Dipeptidyl Peptidase 1 Inhibitor, INS1007, Decreases Surface Proteinase 3 Expression and Neutrophil Serine Protease Activities in Human Neutrophils,” Rheumatology. 58(Supplement …
[cited by applicant]
Canonica, G. W. et al. (May 2020), “Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry,” Respiratory Medicine, vol. 166, 105947, pp.…
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2019/055138 dated Sep. 10, 2020, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/064810, dated Jul. 6, 2023, 6 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2022/027026, dated Nov. 9, 2023, 8 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/048249, mailed Feb. 1, 2023, 8 pages.
[cited by applicant]
Mayo Clinic (Oct. 2021), “Periodontitis,” 4 pages.
[cited by applicant]
Ochsenkuhn, T et al. (Jan. 2018), “P759 Ustekinumab as rescue treatment in therapy-refractory or -intolerant ulcerative colitis” Journal of Crohn's and Colitis, vol. 12, Issue supplement_1, p. S495, 1 page.
[cited by applicant]
Rosati, M. G. et al. (Jan.-Feb. 2016), “Relationships among allergic rhinitis, asthma, and chronic rhinosinusitis,” American Journal of Rhinology and Allergy, vol. 30, No. 1, pp. 44-47.
[cited by applicant]
U.S. National Library of Medicine (Jul. 2017), “History of Changes for Study: NCT02653872,” [Online], Retrieved from the Internet: URL:https://classic.clinicaltrials.gov/ct2/history/NCT02653872?V_6=View#StudyPageTop; 17…
[cited by applicant]
Cited By (2)